Metrics as of 10/14/2026, 08:31 AM (Berlin time), refresh in progress.
HUTCHMED (China) Stock
HUTCHMED (China) Limited
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong SAR China
- CEO
- Chig Fung Cheng
- Employees
- 1,796
- Market cap
- $2.4 B
- IPO
- 16/03/2016
HUTCHMED (China) Limited is a biopharmaceutical firm in the healthcare sector dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Headquartered in Central, Hong Kong, the company was established in 2000 and was…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
HUTCHMED (China) stock: price history
1D
-1.3%
1W
-7.5%
1M
+5.3%
6M
-11.2%
YTD
+1.3%
1Y
-12.3%
2Y
-30.7%
5Y
-59.4%
10Y
+19.5%
Next earnings date
Next earnings date
04/03/2027 (in 138 days)
Volatility around earnings
~28% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vgolden-cross-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Golden Cross
BullishThe 50-day moving average crossed above the 200-day moving average. This is one of the best-known long-term trend-following signals in technical analysis.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about HUTCHMED (China)
Analyst assessment of HUTCHMED (China)
PRICE TARGET LOW
US$13.60
CONSENSUS
US$22.78
MEDIAN
US$16.25
PRICE TARGET HIGH
US$45.00
0
STRONG BUY
8
BUY
1
HOLD
1
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 23/07/2026
HUTCHMED (China) stock metrics
P/E
147.67
P/B
1.88
EV/EBITDA
-115.14
RETURN ON EQUITY
0.6%
NET MARGIN
5.7%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.7%
FLOAT SHARES
170,462,137
AVG. DAILY VOLUME (30D)
80,656
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about HUTCHMED (China) stock
What does HUTCHMED (China) do?
HUTCHMED (China) Limited is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Hong Kong SAR China.
The CEO is Chig Fung Cheng, the company employs around 1,796 people.
The IPO was on 16/03/2016; the stock trades on NASDAQ under the ticker HCM.
What do analysts say about HUTCHMED (China) stock?
10 analysts rate the stock, the consensus is Buy (as of 23/07/2026).
The average price target is US$22.78, ranging from US$13.60 to US$45.00, with a median of US$16.25.
This is an external assessment, not a statement by Market Jury.
When does HUTCHMED (China) report next?
The next earnings date is 04/03/2027.
Around past earnings, price swings were roughly 28% stronger than usual.
Does HUTCHMED (China) pay a dividend?
No, HUTCHMED (China) currently does not pay a dividend.
Which stocks are comparable to HUTCHMED (China)?
Comparable stocks include Regencell Bioscience Holdings, Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris and Lantheus Holdings.
How can I get HUTCHMED (China) stock analyzed?
Clicking "Analyze stock" lets five strategies assess HUTCHMED (China) against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.